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After vaccination of melanoma patients with MAGE antigens, we observed that even in the 
few patients showing tumor regression, the frequency of anti-vaccine T cells in the blood was 
often either undetectable or 
 
 
 
10
 
 
 
5 
 
of CD8 T cells. This frequency being arguably too low for 
these cells to be sole effectors of rejection, we reexamined the contribution of T cells 
recognizing other tumor antigens. The presence of such antitumor T cells in melanoma 
patients has been widely reported. To begin assessing their contribution to vaccine-induced 
rejection, we evaluated their blood frequency in five vaccinated patients. The antitumor 
cytotoxic T lymphocyte (CTL) precursors ranged from 10
 
 
 
4 
 
to 3 
 
  
 
10
 
 
 
3
 
, which is 10–10,000 
times higher than the anti-vaccine CTL in the same patient. High frequencies were also 
observed before vaccination. In a patient showing nearly complete regression after vaccination 
with a MAGE-3 antigen, we observed a remarkably focused antitumoral response. A majority 
of CTL precursors (CTLp’s) recognized antigens encoded by 
 
MAGE-C2
 
, another cancer-
germline gene. Others recognized gp100 antigens. CTLp’s recognizing MAGE-C2 and gp100 
antigens were already present before vaccination, but new clonotypes appeared afterwards. 
These results suggest that a spontaneous antitumor T cell response, which has become 
ineffective, can be reawakened by vaccination and contribute to tumor rejection. This notion 
is reinforced by the frequencies of anti-vaccine and antitumor CTLs observed inside 
metastases, as presented by Lurquin et al. (Lurquin, C., B. Lethé, V. Corbière, I. Théate, 
N. van Baren, P.G. Coulie, and T. Boon. 2004. 
 
J. Exp. Med.
 
 201:249–257).
 
Antitumor CTL clones derived from the blood
or from metastases of melanoma patients by
in vitro stimulation with autologous tumor
cells have been found to recognize several
classes of antigens. First, there are those en-
coded by the “cancer-germline” genes, such as
the 
 
MAGE
 
, 
 
BAGE
 
, 
 
GAGE
 
, and 
 
LAGE
 
 families
(1–5). These genes are expressed in a large
fraction of tumors of various histological types
and therefore code for shared antigens. These
antigens are strictly tumor specific because the
cancer-germline genes are silent in normal
adult tissues with the exception of male germ
cells, which do not carry HLA molecules and
therefore cannot present antigens to T cells.
Three subfamilies of 
 
MAGE
 
 genes are ex-
pressed in tumors: 
 
MAGE-A
 
, which codes for
most of the antigens identified so far, 
 
MAGE-B
 
,
and 
 
MAGE-C
 
. A second major class of tumor
antigens is encoded by genes that are mutated
in tumor cells. These antigens are also strictly
tumor specific, but in most cases they were
observed only in a single tumor with notable
exceptions, such as one encoded by a mutated
 
CDK4
 
 (6). In a third class are antigens en-
coded by melanocytic differentiation genes,
such as 
 
tyrosinase
 
, 
 
Melan-A
 
MART-1
 
, or 
 
gp100
 
Pmel17
 
(7–10).
Antigens encoded by 
 
MAGE
 
 genes have
been used for small-scale therapeutic vaccina-
tion trials of metastatic melanoma patients with
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detectable disease. The vaccines consisted of either antigenic
peptides, a protein, a recombinant poxvirus of the ALVAC-
type encoding two antigenic peptides, or dendritic cells
pulsed with an antigenic peptide (11–14). In the peptide,
protein, and ALVAC-MAGE trials, some evidence of tumor
regression was observed in 
 
 
 
20% of the patients. In the trials
involving dendritic cells, the rates of tumor regression were
not clearly different from those observed with other vaccine
modalities (13).
Our initial work suggested that most vaccinated patients,
including those who displayed tumor regression, did not
have anti-vaccine T cells in the blood at frequencies 
 
 
 
10
 
 
 
4
 
of CD8 T cells. Therefore, we developed a sensitive ap-
proach aimed at detecting low CD8 T cell responses. It is
based on in vitro restimulation of PBMCs with the antigenic
peptide followed by labeling with tetramers. To evaluate
CTL precursor (CTLp) frequencies, these mixed lympho-
cyte–peptide cultures (MLPCs) are performed under limiting
dilution conditions. The tetramer-stained cells of the posi-
tive microcultures are cloned, the lytic specificity of the
clones is verified, and their diversity is analyzed by TCR se-
quencing (15). This approach enables us to detect CTL re-
sponses as low as 8 
 
  
 
10
 
 
 
7 
 
of the CD8 T cells (16).
We have focused our efforts on the detection of CTLs
recognizing the antigenic peptide MAGE-3
 
168-176
 
, which is
encoded by the gene 
 
MAGE-A3
 
 and presented by HLA-A1.
In patients vaccinated with a recombinant canarypox virus of
the ALVAC-type coding for the MAGE-3.A1 peptide, anti–
MAGE-3.A1 CTL responses were found in 3 out of 4 patients
who showed tumor regression and in 1 out of 11 who did not
(15–17). Among seven patients vaccinated with MAGE-3.A1
peptide who showed evidence of tumor regression, only one
had a detectable CTL response (16). Even among those vacci-
nated patients who showed a CTL response, most had a low
frequency of anti–MAGE-3.A1 CTLs in the blood, ranging
between 10
 
 
 
6 
 
and 10
 
 
 
5 
 
of CD8 T cells (15, 17).
These results clearly contradicted our initial view on an-
titumoral vaccination, namely that massive anti-vaccine CTL
responses would be required for tumor rejection. Moreover,
they raised the possibility that the low frequency of anti-vac-
cine CTLs would be insufficient to provide all the specific
effector cells that lyse the tumor cells. Therefore, we set out
to examine whether CTLs directed against other antigens
present on the tumor might provide additional effectors for
the tumor rejections observed after vaccination. As a first
step, we show here the presence of high levels of such anti-
tumor CTLs in the blood of vaccinated patients, and we de-
scribe the antigens recognized by these CTLs in one patient.
In Lurquin et al. (18), which appears in this issue of 
 
JEM
 
, we
describe the distribution of anti-vaccine and other antitumor
CTLs inside the metastases of this patient.
 
RESULTS
High frequencies of antitumor CTLp’s in the blood of 
melanoma patients
 
We selected five metastatic melanoma patients who had
been vaccinated with MAGE antigens (Table I). They were
selected because it had been possible to derive a permanent
cell line from their tumor cells. We set up mixed lympho-
cyte–tumor cell cultures (MLTCs) to estimate the blood fre-
quencies of CTLp’s directed specifically against the tumor.
Purified CD8 blood T cells were stimulated with irradiated
autologous tumor cells in medium containing IL-2, IL-4,
and IL-7. These stimulations were performed in limiting di-
lution conditions with 300–4,000 lymphocytes per micro-
culture (19). After three weekly stimulations, the lytic activity
of the microcultures was tested against the autologous tumor
cells, autologous EBV-transformed B cells, and NK target
K562. We considered as positive those microcultures that ly-
sed tumor cells considerably more than EBV-B and K562
cells. We will refer to the lytic effectors detected in these
MLTCs as “antitumor” CTLs to distinguish them from the
 
Table I.
 
Frequencies of antitumor CTLp’s in vaccinated melanoma patients
 
Antitumor CTLp frequency
 
b
 
Patient Vaccine antigens Tumor regression
 
a
 
Anti-vaccine CTLp frequency
 
b
 
Before After
 
CP64 MAGE-3.A1
 
c
 
 
 
5 
 
  
 
10
 
 
 
5
 
6 
 
  
 
10
 
 
 
5
 
6 
 
  
 
10
 
 
 
4
 
EB81 MAGE-3.A1
 
d
 
MAGE-1.A1
 
 
 
3 
 
  
 
10
 
 
 
6
 
 
 
3 
 
  
 
10
 
 
 
7
 
3 
 
  
 
10
 
 
 
4
 
3 
 
  
 
10
 
 
 
3
 
CP67 MAGE-3.A1
 
d
 
MAGE-1.A1
 
 
 
3 
 
  
 
10
 
 
 
7
 
 
 
3 
 
  
 
10
 
 
 
7
 
5 
 
  
 
10
 
 
 
4
 
10
 
 
 
4
 
BB132 MAGE-3.A1
 
d
 
MAGE-1.A1
 
 
 
10
 
 
 
7
 
 
 
3 
 
  
 
10
 
 
 
7
 
2 
 
  
 
10
 
 
 
3
 
2 
 
  
 
10
 
 
 
3
 
LB2269 MAGE-4.A2
 
e
 
MAGE-10.A2
 
  
 
10
 
 
 
7
 
5 
 
  
 
10
 
 
 
5f
 
6 
 
  
 
10
 
 
 
4
 
6 
 
  
 
10
 
 
 
4
 
a
 
Some evidence of tumor regression observed after vaccination as detailed in Materials and Methods.
 
b
 
Among blood CD8 lymphocytes. The anti-vaccine CTLp frequencies were measured by in vitro restimulation of PBMCs with the antigenic peptide in limiting dilution conditions 
followed by labeling with tetramers. Before and After stands for before and after vaccination.
 
c
 
15 injections of 300 µg of peptide without adjuvant.
 
d
 
Three injections of ALVAC-MAGE followed by three injections of peptides without adjuvant.
 
e
 
Three injections of 300 µg of each peptide with rIL-12.
 
f
 
A similar frequency was already present before vaccination. 
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“anti-vaccine” CTLs, which recognize the vaccine antigen.
Precise criteria and representative results are shown in Fig. 1.
For all five patients, antitumor CTLp’s were found at
high frequencies, i.e., from 10
 
 
 
4 
 
to 3 
 
  
 
10
 
 
 
3 
 
of the CD8 T
cells in the blood after vaccination (Table I). These frequen-
cies were considerably higher than that of the anti-vaccine
CTLs, ranging from 12- to 20,000-fold higher (Table I and
Fig. 2). Antitumor CTLp’s were already present at similar
high frequencies before vaccination (Table I). In two pa-
tients who showed evidence of tumor regression, including
patient EB81 (Fig. 2), the frequencies of antitumor CTLp’s
were 
 
 
 
10-fold higher after vaccination. But this was not ob-
served in the other regressor patient and therefore may not
be significant. The level of antitumor CTLp’s found either
before or after vaccination was not higher in the three re-
gressors than in the two progressor patients.
 
Antigens recognized by antitumor CTLs of patient EB81
 
To establish the relevance of the antitumor T cells observed
at such high frequencies, we set out to identify their target
antigens. We focused our efforts on patient EB81, who had
shown complete regression of a large number of cutaneous
metastases. Stable CTL clones were derived from microcul-
tures of postvaccination lymphocytes that displayed a high
level of antitumor lytic activity and did not lyse EBV-B cells
and K562 (Fig. 3). 15 CTL clones were derived from inde-
pendent microcultures. We were able to identify the anti-
gens recognized by 13 of these 15 CTL clones. Remarkably,
these antigens were encoded by only two genes: 
 
MAGE-C2
 
,
a cancer-germline gene, and 
 
gp100
 
Pmel17, a melanocytic dif-
ferentiation gene (20, 21).
10 of the 15 CTL clones recognized antigens encoded by
MAGE-C2 (Fig. 2). CTL clone 16 recognized the MAGE-
C2336–344 peptide ALKDVEERV on HLA-A2. T cell recep-
tor sequencing indicated that this clonotype was repeated six
times among the 15 CTL clones. Another peptide, MAGE-
C2191–200 LLFGLALIEV, was recognized by three CTL clones,
each having a different TCR. The detailed identification of
these antigens is described elsewhere (22). Finally, one CTL
clone recognized a third peptide, MAGE-C242–50 ASST-
LYLVF, on HLA-B57. All of the clones recognized pep-
tide-pulsed targets with half-maximal lysis at peptide con-
centrations between 20 and 100 nM, the usual range for
such CTLs. Thus, five different clonotypes recognizing three
different MAGE-C2 antigenic peptides constituted the ma-
jority of the antitumor CTL clones derived from the blood
of patient EB81. Two additional clonotypes were found, us-
ing HLA-A2 tetramers, in blood collected 7 mo later (Fig.
2). 3 of the 15 antitumor CTL clones recognized an anti-
genic peptide encoded by gp100, namely gp100209–217 IT-
DQVPFSV, which is presented by HLA-A2 (21). Two had
the same TCR.
These results show that the massive antitumor CTL re-
sponse of patient EB81 is directed against antigens that belong
to the main known classes of tumor antigens. The antitumor
CTL response of this patient was remarkably focused on
MAGE-C2 antigens, targeting three different peptides with
seven different clonotypes, whereas no CTL directed against
other antigens encoded by cancer-germline genes was ob-
served. This is not due to the lack of expression of other can-
cer-germline genes. Although MAGE-C2 appeared to have
the highest expression, several other cancer-germline genes,
such as MAGE-A3,  MAGE-A6, and LAGE-1, were ex-
pressed at similar levels in tumor samples and in the tumor cell
line (Table II). It is worth noting in Table II that the gene ex-
pression profile of the melanoma cell line, which was used to
derive all of the antitumor CTLs of patient EB81, shows a
good match with those of the autologous tumor samples.
Presence of anti–MAGE-C2 and anti-gp100 CTLs 
before vaccination
We observed that a spontaneous CTL response against
MAGE-C2 had already occurred in patient EB81 before
vaccination. Eight independent antitumor CTL clones were
Figure 1. Limiting dilution analysis of antitumor CTLp’s in patient 
EB81. Lytic patterns obtained at days 20 and 27 with limiting dilution 
microcultures set up with 700 and 350 blood CD8 lymphocytes and stim-
ulated with irradiated autologous tumor cells, IL-2, IL-4, and IL-7 on days 
0, 7, 14, and 21. Microcultures deemed to contain specific antitumor T cells 
are boxed. The lytic activity of aliquots of the microcultures was measured 
against autologous tumor cells EB81-MEL, autologous EBV-transformed 
B cells (EB81-EBV), and K562. On day 20 only, effector cells and 
51Chromium-labeled targets were incubated in the presence of a 50-fold 
excess of unlabeled K562 to quench the lytic activity of NK-like effectors. 
Microcultures were considered to contain antitumor CTLs if they satisfied 
on day 20 as well as on day 27 the following criteria: lysis of tumor  10% 
and lysis of EBV-B and K562 lower than one third of the lysis of tumor.ANTITUMOR CTL IN MELANOMA PATIENTS | Germeau et al. 244
obtained from the prevaccination lymphocytes (Fig. 2).
Two recognized the MAGE-C2191–200 peptide (Fig. 2). Both
carried the same TCR. Another CTL clone recognized
gp100154–162.
Considering the presence of CTLs directed against
MAGE-C2 and gp100 both before and after vaccination, we
wondered whether individual CTL clonotypes also had a
constant presence. Some clonotypes were clearly present in
the blood before and after vaccination. An example is anti–
MAGE-C2191–200 CTL clone 11. As shown in Lurquin et al.
(18), its frequency among blood CD8 T lymphocytes was
evaluated with a clonotypic PCR. It was 9   10 6 before
Figure 2. Frequencies and target antigens of antitumor CTLs from 
patient EB81. The clinical evolution of the patient and the frequencies of 
antitumor and anti-vaccine CTLp’s are indicated in the top. Frequencies of 
antitumor CTLp’s were measured by MLTC with a tumor cell line derived 
from the invaded lymph node, whereas those of anti–MAGE-3.A1 and 
anti–MAGE-C2336–344 CTLp’s were measured by clonotypic PCR. The bottom 
panels represent antitumor CTL clones with different numbers for each TCR 
sequence and the occurrence of repeated clones. Most of these CTL clones 
were derived from lymphocytes collected in September 1999 and March 
2000 and were stimulated in autologous MLTC. Additional CTL clones were 
derived from lymphocytes collected in October 2000 by stimulation with 
MAGE-C2 peptides and identification of the positive microcultures with the 
appropriate tetramer. For peptide MAGE-C2336–344, 15 additional CTL clones 
were obtained. 14 turned out to be the CTL 16 clonotype, whereas one, CTL 
40, had another TCR. A similar experiment performed with MAGE-C2191–200 
revealed a new highly repeated clonotype, CTL 41.JEM VOL. 201, January 17, 2005 245
ARTICLE
vaccination and 3   10 5 after vaccination. On the other
hand, some clonotypes found at high frequency after vacci-
nation were not detectable at all before vaccination. An ex-
ample is anti–MAGE-C2336–344 CTL 16. Its frequency in the
blood before vaccination was  7   10 7, whereas after vac-
cination it reached 9   10 5 (Fig. 2). Similar observations
were made with the anti-gp100 CTL. CTL 7 appeared after
vaccination, whereas CTL 14 was already present before.
A more complete description of the frequencies of vari-
ous CTL clonotypes before and after vaccination, not only
in the blood but also inside metastases, is provided in
Lurquin et al. (18).
DISCUSSION
It is well known that tumor-specific T lymphocytes can be
obtained from the blood and from tumor-infiltrating lym-
phocytes of cancer patients, even at the time of tumor pro-
gression. It is with these tumor-specific T cells that most of
the tumor antigens that are used today for vaccination have
been identified. It is generally assumed that such antitumor
T cells are ineffective at rejecting the tumor either because
their frequency is too low, because the tumor cells were se-
lected to escape recognition (23), or because these lympho-
cytes are functionally deficient (24, 25). It is important to
note, however, that this state of functional tolerance is re-
versible in vitro and that adoptive transfer of antitumor T
cells restimulated and amplified in vitro can show clinical ef-
ficacy (26, 27).
Because of the low or even undetectable frequency of
anti-vaccine T cells in patients who show tumor rejection
after vaccination, we wished to evaluate a possible contribu-
tion of other antitumor T cells as specific effectors for the
destruction of tumor cells, which occurs occasionally after
vaccination. All of five vaccinated melanoma patients were
found to have circulating antitumor CTLp’s at frequencies
that were 10–10,000-fold higher than those of the anti-vac-
cine CTLp’s. These results do not contradict previous stud-
ies that suggested that antitumor CTLp’s were present in the
blood of some melanoma patients at frequencies in the range
of 10 4 to 10 3 (19, 28, 29).
To progress in the exploration of the contribution of
these antitumor T cells, we felt that it was necessary to ascer-
tain rigorously their tumor specificity by defining their target
antigens. In one patient, we obtained a synthetic view of the
target antigens recognized by the antitumor T cells, providing
us with completely characterized CTL clonotypes that could
be tracked in blood samples collected at various times and, as
shown in Lurquin et al. (18), also in metastases. The antigens
recognized by the antitumor CTLs of patient EB81 turned
out to belong to the main classes of tumor antigens that have
been defined previously. A majority of antitumor CTL clones
recognized antigens encoded by MAGE-C2, a cancer-germ-
line gene. Others recognized an antigen encoded by gp100, a
melanocytic differentiation gene. As shown in Lurquin et al.
(18), another antitumor CTL clone of patient EB81 recog-
nized an antigen encoded by an ubiquitously expressed gene
that had undergone a point mutation in the tumor.
A high frequency of antitumor CTLs was already present
in all five patients before vaccination. In patient EB81, anti-
gens encoded by MAGE-C2 and gp100 were targets of anti-
tumor T cells found both before and after vaccination. Sev-
eral anti–MAGE-C2 clonotypes were found at frequencies
equal or greater than 10 5 in the blood before vaccination
(see Lurquin et al. [18]). Their cumulative frequency was  7  
10 5. It is noteworthy that in face of such a high prevaccina-
tion T cell response, the tumor had not lost the expression of
the MAGE-C2 target antigens.
In conclusion, it appears that the melanoma patients who
are being vaccinated have already mounted a strong sponta-
neous T cell response against the types of antigens used in the
vaccines. At the time of vaccination, these highly frequent T
cells are clearly ineffective in halting tumor progression. This is
not due to a lack of presence of these cells inside the tumors,
Table II. Expression of cancer-germline and melanocytic 
differentiation genes in tumor cells from patient EB81
Before vaccination After vaccination
cut. met. cut. met. lymph node cell line
Real-time Semiquantitative RT-PCR
MAGE-A
10       
2 507          
3 3559           
40       
6 2320             
8       
9       
10 1159         
11 2       
12 25         
MAGE-B
10       
20       
MAGE-C
1         
2 3941                
LAGE
1 527           
21       
Tyrosinase 29742                
Melan-AMART-1 31442              
gp100 27220            
Tumor samples included a cutaneous metastasis (cut. met.) resected before 
vaccination, in August 1999, a cutaneous metastasis biopsied in December 1999, at 
the time of tumor regression, and an invaded lymph node resected 4 mo later while 
regression of cutaneous metastases carried on. The EB81-MEL tumor cell line was 
derived from the lymph node metastasis. The results of the real-time PCR experiments 
are expressed as number of mRNA/1,000 cells, considering 10 pg total RNA per cell 
and an efficiency of reverse transcription of 25%. The other results are expressed as 
   ,   ,  , or   if the amount of the amplified product is equal or greater than 
that obtained with 1:1, 1:3, 1:9, and 1:27 dilutions of the reference RNA used for each 
gene. Lower levels of expression are scored negative. Reference RNA is extracted from 
tumor cell lines expressing the relevant genes.ANTITUMOR CTL IN MELANOMA PATIENTS | Germeau et al. 246
as shown in Lurquin et al. (18). We also show in this report that
after vaccination, antitumor CTLs are highly concentrated in the
tumors. This reinforces the possibility that they constitute the
main component of the effectors that cause tumor rejection.
One might regard the unexpected observation of tumor re-
jection in the face of a low anti-vaccine CTL response as a mi-
nor issue, fading away with the use of better vaccines. In our
view, this opinion neglects the uncomfortable fact that up to
now no vaccination modality has stood out as producing a su-
perior frequency of tumor rejection, even though higher fre-
quencies of anti-vaccine CTLs are observed in regressing pa-
tients with certain modalities, such as dendritic cell vaccination.
Recruitment of other antitumoral T cells by the anti-vaccine T
cell may therefore be a general feature of any successful vacci-
nation procedure. A possible consequence might be that the
functional properties enabling anti-vaccine T cells to do so
matter more than their number. Elucidating what these func-
tional properties are and how to generate them might be key
to improving anti-tumoral vaccination strategies.
MATERIALS AND METHODS
Patients. The clinical study protocol was approved by the Ethics Review
Committee of the Faculty of Medicine of the Catholic University of Louvain.
Five metastatic melanoma patients with measurable disease at the time of vac-
cination were included in this study. Patient CP64 received 15 injections of
300  g of peptide MAGE-3.A1 without adjuvant. He mounted a monoclo-
nal CTL response to the vaccine antigen (15) and showed an about threefold
volume reduction of a cutaneous metastasis 10 cm in diameter. However,
other metastases progressed or appeared during the same period of time and
the patient died from tumor progression 10 mo after the onset of vaccination.
Patients EB81, CP67, and BB132 received four injections of ALVAC-
MAGE, a recombinant poxvirus containing two minigenes encoding peptide
MAGE-1.A1 (EADPTGHSY) and MAGE-3.A1 (EVDPIGHLY), followed
by three booster vaccinations with 300  g of each peptide. Patient EB81 had
 20 cutaneous metastases on her right leg at the onset of vaccination. By the
third ALVAC vaccination, several of these nodules had flattened, and all cuta-
neous metastases subsequently disappeared slowly. An inguinal adenopathy
appeared 2 mo after the first vaccination and was resected. It was invaded by a
large metastatic nodule. The EB81-MEL tumor cell line was derived from
this invaded node. The patient has remained disease-free for  4 yr since the
resection of this lymph node metastasis. Patient CP67 had cutaneous me-
tastases on the left arm and hand and an axillary lymph node metastasis. All of
these lesions regressed during vaccination over a period of 7 mo. Then new
nodules appeared on the left arm and axillary areas. Patient BB132 displayed
no evidence of tumor regression. The last patient of this study, LB2269, re-
ceived three vaccinations 3 wk apart with 300  g of peptide MAGE-4.A2
(GVYDGREHTV) and 300  g of peptide MAGE-10.A2 (GLYDGMEHL)
injected subcutaneously and intradermally. On the day of each vaccination,
and 2 and 4 d later, 4  g rhIL-12 (Genetics Institute) was injected subcutane-
ously at the vaccine site. The patient had lymph node metastases at the onset
of vaccination, and no tumor regression was observed.
Cells. Melanoma cell lines, EBV-transformed B cells, and K562 were cul-
tured in Iscove’s medium (Life Technologies) supplemented with 10% FCS,
116 mg/L L-arginine, 36 mg/L L-asparagine, and 216 mg/L L-glutamine.
MLTC and MLPC experiments and culture of CTL clones were performed
in Iscove’s medium as described above but with human serum instead of FCS.
Analysis of antitumor CTLs with MLTC. PBMCs isolated by Lym-
phoprep (Nycomed) density gradient centrifugation were cryopreserved in
Iscove’s medium supplemented with 10% human serum and 10% DMSO.
Blood CD8  lymphocytes were purified from thawed PBMCs by sorting
on a FACS Vantage (Becton Dickinson) or with magnetic beads (Miltenyi
Biotec). Lymphocytes were seeded at 200–2,000 cells/well with 48 or 96
wells/cell number in V-bottom microwells (Nunc) and stimulated by the
addition of irradiated (100 Gy) autologous tumor cells (3,000 cells/well)
pretreated with 50 U/ml IFN-  (Roche Diagnostics) in a final volume of
100  l Iscove’s medium supplemented with 10% human serum, 100  M
1-methyl-L-tryptophan, 20 U/ml IL-2, 10 ng/ml IL-4, and 5 ng/ml IL-7.
The microcultures were restimulated each week by the addition of irradi-
ated tumor cells and the same cytokine cocktail. Around day 21, aliquots
collected from all microcultures were used as effector cells in a lysis assay.
51Chromium-labeled target cells included IFN- –treated autologous tumor
cells, autologous EBV-transformed B cells, and K562. Effectors and targets
were incubated for 4 h in the presence of a 50-fold excess of unlabeled
K562 to quench the activity of NK-like lytic effectors. Usually a second ly-
sis assay was performed around day 28 in the same conditions but in the ab-
sence of unlabeled K562 cells.
To derive antitumor CTL clones from microcultures displaying a high level
of lytic activity, effector cells were cloned by limiting dilution and stimulated
with 3,000 irradiated IFN- –treated EB81-MEL cells and 30,000 irradiated allo-
genic LG2-EBV–transformed B cells as feeder cells in 200  l medium containing
50 U/ml IL-2. CTL clones that lysed specifically the tumor cells were restimu-
lated each week with tumor cells and feeder cells as described above.
MLPCs. MLPCs were performed as described previously (17). In brief,
PBMCs from patient EB81 were incubated for 60 min at room temperature
Figure 3. Lytic activity of antitumor CTL clones of patient EB81. Target cells included autologous melanoma cells EB81-MEL ( ), autologous EBV-B 
cells ( ), and K562 cells ( ).JEM VOL. 201, January 17, 2005 247
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with antigenic peptide MAGE-C2191 or MAGE-C2336 at 20  M, washed,
and distributed at 2   105 cells /microwell in 0.2 ml of medium containing
20 U/ml IL-2, 10 ng/ml IL-4, and 10 ng/ml IL-7. On day 7, 50% of the
medium was replaced by fresh medium containing 20  M of peptide, IL-2,
IL-4, and IL-7. Tetramer labeling was performed on day 14 using a control
tetramer as described previously (17).
TCR analysis. Total RNA from CTL clones was extracted with the
TriPure reagent (Roche Diagnostics). Reverse transcription was performed
as described previously (17). cDNA served as template for PCR amplifica-
tions using panels of V - or V -specific upstream primers and one down-
stream C  or C  primer. PCR products were purified and sequenced to
obtain a complete identification of the CDR3 region. Frequency estima-
tions using clonotypic PCR on PBMCs were based on limiting dilution
analysis as described in Lurquin et al. (18).
Gene expression analysis. Expression of cancer-germline and melano-
cytic differentiation genes was assessed by reverse transcription and conven-
tional PCR amplification. Gene expression levels were evaluated semiquan-
titatively by the intensity of the bands obtained by separating PCR products
in agarose gel. Expression of all of these genes in the prevaccination me-
tastasis of patient EB81 was also measured by real-time quantitative PCR
based on TaqMan methodology using the ABI PRISM 7700 Sequence De-
tection System (Applied Biosystems). Sequences of primers and probes are
available from the authors and will be described elsewhere.
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